GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Novartis AG
The share price of Novartis, the Swiss pharmaceutical giant, is determined by its ability to develop and commercialize innovative medicines. A strong portfolio of patented drugs and a focus on cutting-edge therapies, such as gene and cell therapies, have earned investor confidence.
Share prices of companies in the market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant focused on innovative drugs in the oncology, cardiology, and immunology sectors. We classify it as a Pharma Holding, and the chart below shows the overall performance of the entire industry of large drug manufacturers.
Broad Market Index - GURU.Markets
Novartis is a Swiss pharmaceutical giant with a diversified portfolio of innovative drugs across various therapeutic areas. Its scale makes it an important component of the GURU.Markets index. The chart below represents the entire market. Find out how Novartis shares compare to the overall market.
Change in the price of a company, segment, and market as a whole per day
NVS - Daily change in the company's share price Novartis AG
For Novartis, the Swiss pharmaceutical giant, daily price changes reflect sensitivity to research results and patent news. The graph of these fluctuations is unspectacular, but it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
Novartis AG is a global pharmaceutical giant. The chart reflects the average daily volatility of the entire industry, which is dependent on research results. It serves as a benchmark that allows investors to assess how well NVS's diversified drug portfolio protects the company from the risks associated with patent loss.
Daily change in the price of a broad market stock, index - GURU.Markets
Novartis is a Swiss pharmaceutical giant. The pharmaceutical sector can be defensive, but breakthroughs and setbacks in drug development create their own volatility. The chart below shows the overall market dynamics, allowing you to assess how Novartis fits into the global investment landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Novartis AG
Novartis, the Swiss pharmaceutical giant, completed the spinoff of its Sandoz division last year, focusing entirely on innovative medicines. The stock price performance shown in the chart reflects the market's assessment of this new, more focused strategy.
Annual dynamics of market capitalization of the market segment - Pharma holding
Novartis AG, the Swiss pharmaceutical giant, has one of the most diversified drug portfolios in the world. The company actively invests in cutting-edge technologies such as cell and gene therapy. The chart will show whether its focus on innovation allows it to outperform the conservative Big Pharma sector in terms of profitability.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Novartis, a Swiss pharmaceutical giant, focuses on innovative medicines. Its performance is driven by success in new drug development and is largely unaffected by overall economic trends. For investors, this is a story about how scientific research and patents can create value, driving growth that often doesn't correlate with the broader market trajectory.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Novartis AG
Novartis's monthly price fluctuations reflect operational successes and setbacks in drug development. The chart's dynamics are closely linked to news about clinical trials, regulatory decisions on new drugs, and strategic moves such as divestitures or spinoffs of non-core divisions to focus on innovation.
Monthly dynamics of market capitalization of the market segment - Pharma holding
What you see here is the dynamics of the entire pharmaceutical sector, where Novartis is one of the global giants. Its movements reflect general trends, such as pressure on prices and the need for innovation. This is the backdrop against which Novartis is transforming itself, focusing on cutting-edge therapies.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
What you see here is the overall market dynamics. For Novartis, one of the pharmaceutical giants, this is the backdrop. Its movements are generally smoother than those of the market, reflecting the defensive nature of its business and its own history of transformation and focus on innovative drugs.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Novartis AG
Novartis, the Swiss pharmaceutical giant, sees its stock react weekly to clinical trial results, new drug approvals, and strategic decisions such as spinoffs (e.g., Sandoz). The chart reflects how investors evaluate its innovative potential and future sources of growth.
Weekly dynamics of market capitalization of the market segment - Pharma holding
Novartis, like other large pharmaceutical companies, often moves with its sector, reacting to general news. However, strategic moves, such as the spinoff of the Sandoz division, or the success of key drugs can create a unique trajectory. The chart allows you to compare how these corporate events impact its performance relative to its competitors.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Novartis is a Swiss pharmaceutical giant. Big Pharma shares are often considered a safe haven due to their stable demand for medications. Compare Novartis's weekly performance to the market to see if the company truly is a safe haven during market turbulence.
Market capitalization of the company, segment and market as a whole
NVS - Market capitalization of the company Novartis AG
The market capitalization of Novartis, one of the Swiss pharmaceutical giants, reveals how the market views its focus on innovative drugs. The chart reflects investor reactions to successful clinical trials and the launch of new drugs in areas such as cardiology and oncology. The company's valuation is directly dependent on the ability of its scientific pipeline to create new blockbusters.
NVS - Share of the company's market capitalization Novartis AG within the market segment - Pharma holding
Novartis, the Swiss pharmaceutical giant, holds one of the largest market shares thanks to its diversified portfolio of innovative drugs. The company's market capitalization reflects its strong positions in oncology, cardiology, and gene therapy, making it a pillar of the global pharmaceutical industry.
Market capitalization of the market segment - Pharma holding
Here's a chart showing the combined value of the world's leading pharmaceutical companies. Novartis, a Swiss giant, is a pillar of this industry with a strong portfolio in cardiology, oncology, and immunology. The dynamics of this market reflect the world's constant need for innovative medicines, and Novartis plays a key role in their development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Novartis is a Swiss pharmaceutical giant with a robust portfolio of innovative drugs. Its market value reflects the value of its biotech intellectual property. The chart below illustrates the significant share of the economy that a successful drug developer can command.
Book value capitalization of the company, segment and market as a whole
NVS - Book value capitalization of the company Novartis AG
Novartis's assets include a global network of R&D centers, particularly strong in oncology and gene therapy, as well as state-of-the-art manufacturing facilities for innovative drugs. Its book value reflects this scientific and manufacturing prowess. The chart illustrates how strategic investments in breakthrough technologies are shaping the company's future growth.
NVS - Share of the company's book capitalization Novartis AG within the market segment - Pharma holding
Blackstone is one of the world's largest owners of real assets. The chart shows its total stake in physical infrastructure across various sectors, from real estate and logistics parks to energy facilities. The company transforms capital into tangible, income-generating assets.
Market segment balance sheet capitalization - Pharma holding
Novartis is a classic European pharmaceutical giant. The sector's asset chart demonstrates how capital-intensive this industry is. Novartis's success is based on dual investments: in R&D to create new drugs and in a global network of manufacturing and distribution facilities.
Book value of all companies included in the broad market index - GURU.Markets
Novartis, the Swiss pharmaceutical giant, has a significant physical presence. Its book value lies in its cutting-edge research campuses and manufacturing facilities around the world, where innovative drugs, including gene and cell therapies, are developed and manufactured.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Novartis AG
Novartis, the Swiss pharmaceutical giant, has vast assets. The market values it even higher, paying a premium for its diversified drug portfolio and one of the most innovative R&D platforms in the world, including cutting-edge methods such as gene and radioligand therapies.
Market to book capitalization ratio in a market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant with a diversified drug portfolio and a focus on innovative therapies. Its market valuation reflects the value of its current blockbusters and its belief in future scientific breakthroughs. This chart shows how R&D expectations shape the premium it commands over its substantial manufacturing and research asset base.
Market to book capitalization ratio for the market as a whole
Novartis is a Swiss pharmaceutical giant with a diversified portfolio of innovative drugs and generics (via Sandoz). This chart reflects the average market valuation of the business. Against this backdrop, Novartis's valuation shows how investors balance the profitability of its current blockbusters with expectations for future scientific developments and competition.
Debts of the company, segment and market as a whole
NVS - Company debts Novartis AG
For Swiss pharmaceutical giant Novartis, debt is part of a conservative capital management strategy. The company uses debt to fund R&D, targeted acquisitions, and capital returns to shareholders, all while maintaining a high credit rating. This chart demonstrates a balanced approach to leverage.
Market segment debts - Pharma holding
Novartis, the Swiss pharmaceutical giant, invests billions in research and development of new drugs. In this industry, debt financing is often used for two purposes: funding long-term R&D projects and large acquisitions of other companies to gain access to their technologies. This chart allows us to assess Novartis's financial strategy in the context of the global pharmaceutical industry.
Market debt in general
Novartis is a Swiss pharmaceutical giant with a diversified portfolio of innovative drugs. The process of developing and bringing new drugs to market is extremely costly. This chart helps understand the macroeconomic environment in which Novartis finances its research, in terms of capital availability, and how its debt burden compares to industry and market norms.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Novartis AG
Novartis is a Swiss pharmaceutical giant with a strong portfolio of innovative drugs in oncology and cardiology. This chart shows how the company uses its balance sheet to fund research and development. Debt may be used for major M&A transactions aimed at expanding its pipeline and supporting future growth.
Market segment debt to market segment book capitalization - Pharma holding
Novartis is a Swiss pharmaceutical giant with a broad portfolio of innovative drugs. The process of developing new drugs is lengthy and expensive. This chart helps assess how the company manages its financial resources for R&D. It compares its debt to the overall capitalization of the pharmaceutical sector, reflecting its innovation funding policy.
Debt to book value of all companies in the market
Novartis, the Swiss pharmaceutical giant, has significant financial resources to fund its global operations and research. This chart compares its financial policy with the overall market. It shows that Novartis's debt burden is moderate compared to the average debt level for the entire economy.
P/E of the company, segment and market as a whole
P/E - Novartis AG
This metric for Novartis, the Swiss pharmaceutical giant, reflects the company's valuation after focusing on innovative drugs. The P/E ratio shows how investors assess the potential of its current pipeline and developments that are expected to become future growth drivers. It's a bet on science and the company's ability to create new blockbusters.
P/E of the market segment - Pharma holding
Novartis AG is a Swiss pharmaceutical giant focused on innovative drugs, from gene therapy to radiopharmaceuticals. The company is constantly transforming its portfolio. This chart shows the average valuation for the European pharmaceutical industry, allowing investors to compare how Novartis's scientific potential compares to its competitors.
P/E of the market as a whole
Novartis AG is a Swiss pharmaceutical giant focused on innovative drugs. The company's valuation is determined by its ability to develop and market new drugs that have the potential to become blockbusters. While this chart reflects overall economic sentiment, for Novartis, news from its research labs and regulatory decisions are far more important.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Novartis AG
Novartis AG is a Swiss pharmaceutical giant that, following its restructuring, has focused on innovative medicines. This chart shows market expectations for its research potential. The company's valuation is based on the expected success of clinical trials and the commercial potential of new drugs capable of becoming leaders in their therapeutic areas.
%20P%2FE%20Novartis%20AG&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Novartis-AG&v=1772623936156 "Chart of the company's future (projected) P/E Novartis AG")
Future (projected) P/E of the market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant focused on innovative drugs in areas such as oncology and immunology. The company's success depends on research and development. This chart reflects the market's confidence in its scientific potential. Comparing Novartis's profit forecasts to the sector reveals how highly investors value its pipeline of future drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772623936158 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
Novartis is a Swiss pharmaceutical giant with a strong portfolio of innovative drugs across various therapeutic areas. Like other large pharmaceutical companies, internal events such as new drug approvals are more important than overall market trends. However, this overall risk appetite graph still influences how investors evaluate the entire sector.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772623936175 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Novartis AG
Novartis AG is a Swiss pharmaceutical company with a diversified portfolio of innovative medicines and generics (through its Sandoz division). The company's profits depend on successful sales of its patented drugs and the effectiveness of its research. This chart shows how scientific developments and strategic decisions translate into financial results.
Profit of companies in the market segment - Pharma holding
Novartis AG is a Swiss pharmaceutical giant with a strong portfolio of innovative medicines in areas such as oncology, cardiology, and immunology. The company actively invests in cutting-edge research, including gene therapy. Its ability to bring new blockbusters to market is a key factor in the growth and profitability of the entire global pharmaceutical industry.
Overall market profit
Novartis is a Swiss pharmaceutical company, one of the world's leading developers and manufacturers of innovative medicines. Its portfolio includes drugs for the treatment of oncology, cardiovascular disease, and rare diseases. Novartis' success in developing breakthrough therapies not only transforms medicine but also makes a significant contribution to the overall profitability of the healthcare sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Novartis AG
Novartis is a Swiss pharmaceutical giant focused on developing innovative medicines. The profit forecasts included in this chart are based on the potential of its current blockbusters and the viability of its R&D pipeline. The success of new drugs in key therapeutic areas determines future revenue.
%20profit%20of%20the%20company%20Novartis%20AG&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Novartis-AG&v=1772623936199 "Graph of future (projected) profit of the company Novartis AG")
Future (predicted) profit of companies in the market segment - Pharma holding
Novartis AG is a Swiss pharmaceutical company focused on innovative drugs in areas such as oncology and cardiology. This chart shows the projected profit trajectory for the entire pharmaceutical industry. This allows one to compare the potential of Novartis' new developments with analysts' overall expectations for the global drug market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772623936202 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
This chart illustrates expectations for the Swiss pharmaceutical giant. Novartis's profit forecast hinges on the success of its innovative drugs, particularly in cardiology, oncology, and immunology. The trend reflects analysts' confidence in the company's product portfolio following the spinoff of its generics business, Sandoz, and its focus on patented drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772623936203 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Novartis AG
Novartis is a Swiss pharmaceutical giant with a broad portfolio of innovative drugs. This chart shows how investors value its revenue based on the research and development of new drugs. The dynamics of the multiple reflect market expectations regarding the success of clinical trials and the commercial potential of the future portfolio.
P/S market segment - Pharma holding
Novartis is a Swiss pharmaceutical company focused on innovative medicines in oncology, cardiology, and immunology. This metric reflects the average revenue estimate in the pharmaceutical industry and provides an insight into how investors perceive Novartis's drug portfolio and research capabilities compared to its competitors.
P/S of the market as a whole
Novartis is a Swiss pharmaceutical giant with a diversified drug portfolio and a focus on innovative treatments such as cell and gene therapies. This chart, which displays the average market revenue estimate, helps investors understand Novartis's scientific potential and its ability to generate future revenue from breakthrough technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Novartis AG
Novartis is a Swiss pharmaceutical giant that, following a restructuring, has shifted its focus to innovative medicines. The company's future revenue estimates are based on expectations for its portfolio of patented drugs in areas such as oncology and cardiology. This chart reflects investor confidence in Novartis's ability to develop and commercialize breakthrough treatments.
%20P%2FS%20Novartis%20AG&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Novartis-AG&v=1772623936237 "The graph of the company's future (projected) P/S Novartis AG")
Future (projected) P/S of the market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant with an innovative portfolio of drugs across various therapeutic areas. This chart shows how investors view its future earnings. Do they believe in the potential of its R&D pipeline and its ability to bring new blockbusters to market to sustain growth in a highly competitive industry?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772623936250 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
Novartis, the Swiss pharmaceutical giant, has one of the strongest and most diversified portfolios of innovative drugs. The company's ability to successfully launch new drugs and grow revenue is an important factor in assessing the entire sector. This contributes to the overall positive sentiment reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772623936270 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Novartis AG
Novartis AG is a Swiss pharmaceutical company that develops and manufactures innovative medicines and generics. Its revenue is directly dependent on successful sales of patented drugs in key therapeutic areas. This chart reflects the demand for its medical solutions in the global healthcare market.
Sales of companies in the market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant with a strong portfolio of drugs in oncology, cardiology, and immunology. The company focuses on breakthrough scientific developments, including gene therapy. This chart shows the total revenue of the pharmaceutical sector, demonstrating the overall scale and dynamics of the market, in which Novartis strives to achieve a leading position through innovation.
Overall market sales
Novartis is a Swiss pharmaceutical giant with a diversified portfolio of innovative drugs and generics. The company is a leader in research and development. This overall economic activity impacts Novartis through healthcare budgets and patient affordability, which determines the availability and sales of its medications worldwide.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Novartis AG
Novartis is a Swiss pharmaceutical giant with a strong portfolio of innovative drugs in cardiology, immunology, and oncology. The company's future revenue is determined by the success of its key drugs and the results of its research and development. This chart reflects the Wall Street consensus forecast for sales of its patented drugs and the potential for new developments.
%20sales%20of%20the%20company%20Novartis%20AG&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Novartis-AG&v=1772623936377 "Schedule of future (projected) sales of the company Novartis AG")
Future (projected) sales of companies in the market segment - Pharma holding
Novartis is a Swiss pharmaceutical company and a global leader in the development and production of innovative medicines. This chart shows projected revenues for the entire pharmaceutical sector. It provides investors with a general understanding of the industry's growth prospects, allowing them to better assess the potential of Novartis' research programs and new drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772623936409 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
Novartis AG is a Swiss pharmaceutical giant with a broad portfolio of innovative drugs. Like other companies in the sector, demand for its products is relatively stable. However, this chart, which shows global economic forecasts, is important for assessing long-term prospects. The economic well-being of countries determines their ability to finance modern healthcare systems and purchase advanced drugs.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772623936436 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Novartis AG
Novartis is a Swiss pharmaceutical giant with a diversified portfolio of innovative drugs and generics (through its Sandoz division). This chart demonstrates the financial returns from successful research and development. The company's performance is directly dependent on the life cycle of its blockbuster drugs and its ability to continually expand its portfolio with new products.
Market segment marginality - Pharma holding
Novartis AG is a Swiss pharmaceutical company with a diversified portfolio including innovative drugs and advanced therapeutic platforms. Its focus on research-intensive areas, such as gene therapy, creates the potential for future blockbusters. This metric reflects how strong R&D and successful drug launches drive its operational efficiency.
Market marginality as a whole
Novartis is a Swiss pharmaceutical giant with a diversified portfolio of innovative drugs and generics. This chart shows average profitability across the economy. It illustrates the ongoing challenge of pharmaceutical companies: investing billions in R&D to create new blockbusters that can maintain high profitability after patents expire.
Employees in the company, segment and market as a whole
Number of employees in the company Novartis AG
Novartis is a Swiss pharmaceutical giant focused on innovative drugs such as gene and cell therapies. This chart illustrates the size of its global research and sales team. Changes in headcount may reflect portfolio restructuring, a focus on cutting-edge scientific areas, and the spinoff of non-core assets.
Share of the company's employees Novartis AG within the market segment - Pharma holding
This indicator reflects Novartis's scale as one of the largest pharmaceutical giants. Its significant sector-specific workforce underscores the global reach of its operations, from research and development to manufacturing and marketing. This human capital enables the company to maintain a diversified portfolio of patented and generic drugs.
Number of employees in the market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant and one of the world's leaders in innovative drug development. The company invests billions in R&D, making it a magnet for top biologists and chemists. The graph below reflects the science-intensive nature of modern pharmaceuticals, where Novartis sets the highest standards for researchers.
Number of employees in the market as a whole
Novartis is a Swiss pharmaceutical giant with a strong focus on innovative treatments such as gene therapy and radioligands. The company places a premium on breakthrough, high-margin drugs. This graph of total employment shows the economic basis that allows the healthcare system to pay for these cutting-edge (and very expensive) treatments, funding Novartis's continued research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Novartis AG (NVS)
Novartis, the Swiss pharmaceutical giant, invests billions in research and development. Its value depends on the success of these investments. Its high market valuation per employee reflects the value of its patent portfolio and investors' faith in the future breakthroughs of its scientific team.
%20of%20the%20company%20Novartis%20AG%20(NVS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Novartis-AG-NVS&v=1772623936783 "Chart of market capitalization per employee (in thousands of dollars) of the company Novartis AG (NVS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
After spinning off its generics division, Sandoz, Novartis became a pure-play innovator focused on breakthrough medicines (including cell and gene therapies). This chart shows the market value per employee in this new, science-focused organization, reflecting the value of its R&D pipeline.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772623936804 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
Novartis is a Swiss pharmaceutical giant with a diversified drug portfolio. The high market valuation per employee in this chart is a direct result of successful R&D investments. The company's value lies in its patents for innovative treatments, making its human capital—its scientists—invaluable.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772623936920 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Novartis AG (NVS)
Novartis is a Swiss pharmaceutical giant focused on innovative medicines (oncology and cardiology). The company actively utilizes cutting-edge technologies, such as cell and gene therapy. This graph shows the return on investment in research. Success in developing breakthrough, high-value treatments directly translates into high profitability per employee.
%20Chart%20Novartis%20AG%20(NVS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Novartis-AG-NVS&v=1772623936970 "Company Profit Per Employee (in thousands of dollars) Chart Novartis AG (NVS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant. This chart shows the average for the pharmaceutical industry. This sector thrives on R&D and patents. The average return on personnel is high here, as a single successful blockbuster drug can generate tens of billions, covering all the costs of staffing scientists and marketers.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772623936988 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
Novartis is a Swiss pharmaceutical company and one of the global market leaders. Its strategy is based on scientific innovation and the development of patented drugs for the treatment of complex diseases. This metric illustrates the economics of an R&D-intensive industry: breakthrough discoveries and patented products generate high profitability per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772623937043 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Novartis AG (NVS)
Novartis is a Swiss pharmaceutical giant developing innovative drugs. This metric illustrates how a team of scientists and marketers can generate billions for the company. It's a classic example of a business where productivity is based on intellectual property and the successful launch of patented drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Novartis-AG-NVS&v=1772623937078 "Sales chart per company employee Novartis AG (NVS)")
Sales per employee in the market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant focused on innovative drugs after spinning off generics (Sandoz). This chart compares revenue per employee to the segment average. It demonstrates how productive their R&D and commercial teams are in developing and promoting new drugs compared to other Big Pharma players.
Sales per employee for the market as a whole
Novartis is a Swiss pharmaceutical giant with a strong portfolio in oncology, cardiology, and immunology. The company actively utilizes cutting-edge technologies (gene therapy). This metric, like that of other pharmaceutical companies, reflects the value of their intellectual property. A successful patent translates into billions of dollars in revenue generated by a team of researchers and marketers.
Short shares by company, segment and market as a whole
Shares shorted by company Novartis AG (NVS)
Novartis is a Swiss pharmaceutical giant focused on innovative drugs (following the spinoff of Sandoz). The bearish bets seen on this chart are often associated with high R&D risk. Bears may bet on key drugs failing in Phase III clinical trials or on the failure of new drugs to replace the revenues of older blockbusters.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Novartis-AG-NVS&v=1772623937159 "Short Shares Chart for the Company Novartis AG (NVS)")
Shares shorted by market segment - Pharma holding
Novartis, the Swiss pharmaceutical giant, focuses on innovative drugs, particularly in oncology, immunology, and cardiology. This chart shows the overall sentiment towards the sector. It reflects investors' collective bets that "big pharma" will face increased generic competition or clinical trial setbacks.
Shares shorted by the overall market
Novartis is a Swiss pharmaceutical giant focused on innovative medicines. Like other Big Pharma companies, it generates stable cash flows. This chart measures overall market fear. During periods when investors are risk-averse, Novartis shares, with their non-cyclical demand and stable dividends, become an attractive safe haven.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Novartis AG (NVS)
Novartis, a Swiss pharmaceutical giant, focuses on innovative drugs. This indicator above 70 may indicate optimism about its R&D portfolio or strong sales. Oversold territory (<30) may reflect concerns about patent expirations or clinical trial failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Novartis-AG-NVS&v=1772623937281 "RSI 14 indicator chart for the company's stock Novartis AG (NVS)")
RSI 14 Market Segment - Pharma holding
Novartis (NVS) is a Swiss pharmaceutical giant that restructured to focus exclusively on innovative, patented drugs. This metric measures the "temperature" of the entire pharmaceutical sector. It helps understand: is NVS oversold due to its patent risks or is there a general cooling toward Big Pharma?
RSI 14 for the overall market
Novartis is a Swiss pharmaceutical giant that, after spinning off Sandoz (generics), focused on innovative, high-margin drugs. This chart shows the general sentiment of the "crowd," whether the market is euphoric or panicked. This helps assess how closely investor sentiment aligns with Novartis's long-term scientific developments.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NVS (Novartis AG)
The consensus forecast for Novartis is an assessment of its "new" focus. Following the spinoff of generics (Sandoz), analysts are looking exclusively at the innovative pharmaceutical portfolio. Their target prices depend on the success of blockbusters (Entresto, Kisqali) and breakthrough R&D platforms. This is a bet that the "pure" pharma model will grow faster and with higher margins.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NVS-Novartis-AG&v=1772623937386 "A chart showing analyst consensus forecasts for the expected stock price. NVS (Novartis AG)")
The difference between the consensus estimate and the actual stock price NVS (Novartis AG)
Novartis AG is a Swiss pharmaceutical giant focused on innovative drugs (since the spinoff of Sandoz), particularly in cardiology and oncology. This chart shows the gap between the consensus estimate and the price. It illustrates whether analysts believe the company's R&D pipeline is capable of generating new blockbusters and driving growth that the market hasn't yet priced in.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NVS-Novartis-AG&v=1772623937423 "A chart showing the difference between the consensus forecast and the actual stock price. NVS (Novartis AG)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
Novartis is a Swiss pharmaceutical giant focused on innovative treatments, including cell and gene therapies. This chart shows the collective opinion of analysts on the outlook for "big pharma" as a whole. It helps us understand whether experts expect breakthroughs in R&D or consider the sector too conservative.
Analysts' consensus forecast for the overall market share price
Novartis is a Swiss pharmaceutical giant focused on innovative drugs. It's a classic defensive stock. This chart shows the overall consensus forecast for the market. It helps understand what investors value more: defense (during a bearish price) or growth. During periods of panic, investors often park their money in stable stocks like NVS.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Novartis AG
Novartis is a Swiss pharmaceutical giant. Following the recent spinoff of its generics division (Sandoz), the company has focused entirely on developing innovative, patented drugs. This chart reflects an assessment of their R&D potential. The market is weighing their current blockbusters against future therapeutic breakthroughs needed for growth.
AKIMA Market Segment Index - Pharma holding
Novartis is a Swiss pharmaceutical giant focused on innovative drugs in cardiology, immunology, and neurology. This composite metric evaluates R&D and growth. The graph shows the average value for the segment. This benchmark allows one to assess the extent to which Novartis' R&D pipeline enables it to be more efficient than the average pharmaceutical company.
The AKIM Index for the overall market
Novartis is a Swiss pharmaceutical giant focused on developing innovative drugs in areas such as oncology, cardiology, and neuroscience, following the spinoff of generics (Sandoz). This chart, reflecting the market average, provides macro context. It helps assess how Novartis, whose success depends on R&D and patents, compares to the broader economic trends that influence investor sentiment.
